tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Apr 1;28(5).
doi: 10.3201/eid2805.220141. Online ahead of print.
Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Aharona Glatman-Freedman, Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker
Abstract
We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%-97.5%) for persons 16-59 years of age and 93.1% (95% CI 91.8%-94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16-59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2-3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%-84.2%) and 61.3% (52.5%-68.4%) for persons 16-59 years and >60 years. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.
Keywords: BNT162b2; COVID-19; Israel; Pfizer-BioNTech; SARS-CoV-2; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.
. 2022 Apr 1;28(5).
doi: 10.3201/eid2805.220141. Online ahead of print.
Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Aharona Glatman-Freedman, Michal Bromberg, Yael Hershkovitz, Hanna Sefty, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker
- PMID: 35361311
- DOI: 10.3201/eid2805.220141
Abstract
We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%-97.5%) for persons 16-59 years of age and 93.1% (95% CI 91.8%-94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16-59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2-3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%-84.2%) and 61.3% (52.5%-68.4%) for persons 16-59 years and >60 years. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.
Keywords: BNT162b2; COVID-19; Israel; Pfizer-BioNTech; SARS-CoV-2; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.
